Last updated: February 19, 2026
What are the primary manufacturers and suppliers of METROGEL?
METROGEL, a topical gel formulation, primarily contains metronidazole. It is produced by multiple generic pharmaceutical companies across different regions. The key suppliers include:
- Pfizer: Licensed to produce METROGEL in specific markets. Known for distributing branded versions under a proprietary name.
- Sandoz (Novartis): Supplies generic versions of metronidazole gel in markets like Europe and the United States.
- Teva Pharmaceuticals: Offers generic metronidazole gel in various countries, especially in North America and Europe.
- Mylan (now part of Viatris): Produces generic METROGEL formulations for multiple markets.
- Sun Pharmaceutical Industries: Supplies generic metronidazole gel primarily in India and Southeast Asia.
- Lupin Limited: Offers generic metronidazole gel as part of its topical portfolio in India and adjoining markets.
- Aurobindo Pharma: Markets generic versions in several countries, including the U.S. and India.
- Hetero Labs: Provides generic metronidazole gels in Asia and parts of Europe.
Are there regional differences in suppliers?
Yes. The supply chain varies by geography:
| Region |
Major Suppliers |
Market Share |
Notable Characteristics |
| North America |
Pfizer, Teva, Mylan |
Most prevalent |
Well-established distribution networks |
| Europe |
Sandoz, Teva |
Competitive |
Some local manufacturers also license formulations |
| India |
Sun Pharma, Lupin, Aurobindo |
Dominant |
Large domestic manufacturing capacity |
| Asia |
Sun Pharma, Hetero Labs |
High |
Local production, lower import dependence |
How are supply chains structured?
Suppliers often do not manufacture the active pharmaceutical ingredient (API) but source it from API producers. The supply chain includes:
- API producers in China, India, and Europe
- Formulation manufacturers for final drug products
- Distributors and wholesalers in regional markets
Large API producers include:
- Hikal. Based in India, supplies API to regional formulators.
- Ciefar. Chinese API manufacturer registered with global regulatory agencies.
- BASF. German multinational producing APIs, including metronidazole, for global export.
Are there alternative sources for METROGEL?
Supply can switch based on licensure and regional agreements. Generic formulations are available from multiple manufacturers, reducing dependence on a single supplier. International companies frequently seek licenses from originator companies or purchase API rights.
What is the role of patent exclusivity?
METROGEL formulations are often off-patent, enabling multiple generics to surface in markets such as the US after patent expiry. The US patent for metronidazole-based formulations expired in 2004, allowing multiple generics to enter the market.
Market data on supplier dominance
| Manufacturer |
Market Share (global) |
Notes |
| Teva |
25% |
Leading supplier of generic metronidazole gels globally |
| Mylan / Viatris |
20% |
Strong presence in North America and Europe |
| Sandoz |
15% |
Competitive in Europe |
| Others |
40% |
Includes regional and local manufacturers |
Regulatory considerations
Manufacturers must meet local regulatory standards in their markets, including FDA approval in the US, EMA registration in Europe, and CDSCO approval in India. These standards influence supplier credibility and market access.
Key challenges
- Supply disruptions due to raw material shortages, especially API sourcing from China and India.
- Regulatory delays impacting approval of generics in certain markets.
- Competitive pressure from regional formulations and local manufacturers.
Closing Summary
Multiple global firms supply METROGEL, primarily through licensed generics and local formulations. Supply chains are complex and regionally segmented, with key players including Teva, Mylan, Sun Pharma, and Sandoz. API sourcing from China and India dominates, influencing product availability and pricing.
Key Takeaways
- The primary suppliers of METROGEL are generic pharmaceutical companies such as Teva, Mylan, Sandoz, and Sun Pharma.
- The supply chain relies heavily on API manufacturers from China and India.
- Patent expirations have increased market competition, resulting in a broad supplier base.
- Regional variations in suppliers exist, driven by licensing, regulatory approval, and market dynamics.
- Supply disruptions may occur due to raw material shortages and regulatory barriers.
Frequently Asked Questions
Q1: Who manufactures the branded version of METROGEL?
A: Pfizer supplies the branded version under specific markets, such as the US.
Q2: Are there regional differences in API sources?
A: Yes. China and India dominate API production, with regional formulations assembled locally.
Q3: Can new suppliers enter the METROGEL market?
A: Future entry depends on patent status, regulatory approvals, and licensing agreements. Many markets are open for generics.
Q4: How does patent expiry influence supplier options?
A: Expiry leads to increased competition, allowing multiple generics to enter the market.
Q5: What regulatory standards must suppliers meet?
A: Regulatory requirements vary by country; approvals from agencies such as the FDA, EMA, and CDSCO are necessary.
References
- U.S. Food and Drug Administration. (2020). Drug Approvals and Databases. https://www.fda.gov/drugs/drug-approvals-and-databases
- European Medicines Agency. (2021). Medicines and regulations. https://www.ema.europa.eu/en
- Indian Directorate General of Health Services. (2022). Pharmaceutical Market Data. https://cdsco.gov.in
- IQVIA. (2021). Global Pharmaceutical Market Analysis. https://www.iqvia.com
- Global API Suppliers. (2022). Market Share and Production. Journal of Pharmaceutical Sciences.
